The National Institutes of Health announced Monday it has begun an early-stage clinical trial to test a universal flu shot based on mRNA technology.
The National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), an arm of the NIH, has started enrolling volunteers at Duke University in Durham, North Carolina.
We knew the medical industrial complex wanted to expand the use of mRNA technology.
And the flu shot will have the same technology as Pfizer and Moderna’s toxic COVID-19 mRNA gene therapies.
The universal flu vaccine trial will enroll up to 50 healthy people ages 18 through 49 to test whether the experimental shot is safe and produces an immune response, according to NIH. https://t.co/vXFVz86aAc
— NBC News (@NBCNews) May 16, 2023
Whoomp, there it is! “A universal flu vaccine would be a major public health achievement and could eliminate the need for both the annual development of seasonal flu vaccines and the need for patients to get a flu shot every year,” said Acting NIAID Director Hugh Auchincloss, MD…
— Brook Jackson 💜 (@IamBrookJackson) May 16, 2023
Scientists hope the vaccine will protect against a wide variety of flu strains and provide long-term immunity so people do not have to receive a shot every year.
Messenger RNA, or mRNA, is the technology behind Moderna’s and Pfizer’s widely used Covid vaccines. NIH played a crucial role in developing the mRNA platform used by Moderna.
“A universal flu vaccine could serve as an important line of defense against the spread of a future flu pandemic,” Dr. Hugh Auchincloss, acting director of National Institute of Allergy and Infectious Diseases, said in a statement Monday.
This article fails to mention ANY of the controversy related to mRNA technology.
— Wall Street Silver (@WallStreetSilv) May 16, 2023
“Moreover, some strains of influenza virus have significant pandemic potential. A universal flu vaccine could serve as an important line of defense against the spread of a future flu pandemic,” Dr. Hugh Auchincloss added.
From the NIH:
A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.
The trial will enroll up to 50 healthy volunteers aged 18 through 49. Three groups of study participants (10 participants each) will be vaccinated with 10, 25 and 50 micrograms of the experimental vaccine, respectively. After evaluation of the data to determine an optimum dosage, an additional 10 participants will be enrolled to receive the optimum dosage. The study also will include a group of participants who will receive a current quadrivalent seasonal influenza vaccine. This will allow the researchers a point of direct comparison between the immunogenicity and safety of the candidate vaccine and available seasonal flu vaccines. Participants will be regularly evaluated to assess the vaccine’s safety (and, secondarily, its efficacy) and will receive follow-up appointments for up to one year after vaccination.
The early-stage trial is being conducted through the Collaborative Influenza Vaccine Innovation Centers (CIVICs)(link is external) program, which was created by NIAID in 2019 to support the development of broadly protective and longer-lasting flu vaccines. It is the first investigational universal flu vaccine candidate to be tested by the CIVICs program, and was manufactured at the facilities of the Duke Human Vaccine Institute (DHVI), which is a part of the CIVICs program.
A similar vaccine developed by researchers at NIAID’s VRC already has shown positive results in early clinical trials. Both vaccines use a specific portion of a flu protein, hemagglutinin (HA), to induce a broad immune response against influenza. While one portion of the HA protein, known as the head, tends to change as the flu virus spreads and evolves, a more stable portion, known as the stem, evolves very slowly and is very similar across many different types of the flu virus. By using the HA stem as the basis for a vaccine, researchers hope to induce long-term immunity against a broad range of flu viruses. Unlike the VRC’s earlier vaccine, the H1ssF-3928 mRNA-LNP vaccine candidate uses a messenger RNA (mRNA) platform. By developing and testing a variety of different platforms for a universal flu vaccine, researchers are more likely to find one that is both safe and provides strong and broad immunity against a variety of strains.